首页> 美国卫生研究院文献>The California Journal of Emergency Medicine >Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department
【2h】

Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department

机译:急诊科急用华法林逆转4因子凝血酶原复合物浓缩液与新鲜冷冻血浆的血栓栓塞风险

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionWarfarin is a potent anticoagulant used for the prevention and treatment of venous and arterial thrombosis. Occasionally, patients require emergent warfarin reversal due to active bleeding, supratherapeutic international normalized ratio, or emergent diagnostic or therapeutic interventions. Various agents can be used for emergent warfarin reversal, including fresh frozen plasma (FFP) and 4-factor prothrombin complex concentrate (4F-PCC). Both FFP and 4F-PCC are generally considered safe; however, both agents contain coagulation factors and have the potential to provoke a thromboembolic event. Although clinical trials have compared the efficacy and safety of FFP and 4F-PCC, data are limited comparing the risk of thromboembolism between the two agents.
机译:简介华法林是一种有效的抗凝剂,用于预防和治疗静脉和动脉血栓形成。有时,由于活动性出血,超治疗国际标准化比率或紧急诊断或治疗干预,患者需要紧急撤出华法林。各种药物均可用于紧急的华法林逆转,包括新鲜的冷冻血浆(FFP)和4因子凝血酶原复合浓缩物(4F-PCC)。通常认为FFP和4F-PCC都是安全的;但是,这两种药物均含有凝血因子,并有可能引发血栓栓塞事件。尽管临床试验已经比较了FFP和4F-PCC的功效和安全性,但比较两种药物之间血栓栓塞风险的数据仍然有限。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号